Subtyping non-small cell lung cancer by histology-guided spatial metabolomics

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  M. Rafat,et al.  Lipids in the tumor microenvironment: From cancer progression to treatment. , 2020, Progress in lipid research.

[3]  J. Eshleman,et al.  IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution , 2020, Cancer medicine.

[4]  E. Nadal,et al.  Exploiting metabolic vulnerabilities of Non Small Cell Lung Carcinoma. , 2020, Seminars in cell & developmental biology.

[5]  Jing-Yang Huang,et al.  The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients , 2019, Journal of Cancer Research and Clinical Oncology.

[6]  M. Schabath,et al.  Cancer Progress and Priorities: Lung Cancer , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[7]  Xiaofei Li,et al.  Accurate Classification of Non-small Cell Lung Cancer (NSCLC) Pathology and Mapping of EGFR Mutation Spatial Distribution by Ambient Mass Spectrometry Imaging , 2019, Front. Oncol..

[8]  Elizabeth C. Randall,et al.  Rapid MALDI mass spectrometry imaging for surgical pathology , 2019, npj Precision Oncology.

[9]  A. Yoshizawa,et al.  The Ratios of monounsaturated to saturated phosphatidylcholines in lung adenocarcinoma microenvironment analyzed by Liquid Chromatography-Mass spectrometry and imaging Mass spectrometry , 2019, Scientific Reports.

[10]  A. Lane,et al.  Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes , 2019, British Journal of Cancer.

[11]  D. Placantonakis,et al.  Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics , 2019, Front. Oncol..

[12]  Yanjun Wang,et al.  IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5 , 2018, Royal Society Open Biology.

[13]  L. Tafe,et al.  Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. , 2018, Human pathology.

[14]  Jian-ming Hu,et al.  Serum proton NMR metabolomics analysis of human lung cancer following microwave ablation , 2018, Radiation Oncology.

[15]  F. Askin,et al.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. , 2017, Seminars in cancer biology.

[16]  Huqin Zhang,et al.  Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies , 2017, Oncotarget.

[17]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[18]  N. Pavlova,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[19]  H. Dienemann,et al.  Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles , 2015, International journal of cancer.

[20]  A. Walch,et al.  MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice , 2015, Laboratory Investigation.

[21]  Zhili Li,et al.  Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging , 2014, Scientific Reports.

[22]  Y. Hannun,et al.  On-Tissue Localization of Ceramides and Other Sphingolipids by MALDI Mass Spectrometry Imaging , 2014, Analytical chemistry.

[23]  D. Rakheja,et al.  IDH mutations in acute myeloid leukemia. , 2012, Human pathology.

[24]  J. Zo,et al.  Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type. , 2012, Lung cancer.

[25]  S. Digumarthy,et al.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Sanjay Mukhopadhyay,et al.  Subclassification of Non-small Cell Lung Carcinomas Lacking Morphologic Differentiation on Biopsy Specimens: Utility of an Immunohistochemical Panel Containing TTF-1, Napsin A, p63, and CK5/6 , 2011, The American journal of surgical pathology.

[27]  R. Caprioli,et al.  MALDI Imaging Mass Spectrometry – Painting Molecular Pictures , 2010, Molecular oncology.

[28]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[29]  R. Abagyan,et al.  METLIN: A Metabolite Mass Spectral Database , 2005, Therapeutic drug monitoring.

[30]  K. Schwamborn.  The Importance of Histology and Pathology in Mass Spectrometry Imaging , 2017, Advances in cancer research.

[31]  Craig E. Grossman.  Non-small Cell Lung Cancer , 2016 .

[32]  António S. Barros,et al.  NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma. , 2015, Carcinogenesis.

[33]  J. Uhm.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2010 .

[34]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.